Dr. Early Presents Genemarkers’ New Cannabidiol (CBD) Gene Expression Panel at the Society of Cosmetic Chemists (SCC) Annual Meeting
Bridget Early, PhD, detailed how a new gene expression panel developed by Genemarkers tests the biological efficacy of CBD extracts and the cosmetic formulas containing them at the Annual Scientific Meeting & Technology Showcase.
CBD is a non-psychoactive cannabinoid extracted from the hemp plant. Its effects are mediated through the CB1 and CB2 skin receptors, whose expression initiates signaling cascades relevant to both pain and inflammation.
Leveraging her background in chemistry and molecular biology, Dr. Early explained how products derived from cannabis have the potential to act upon the endocannabinoid system.
“Our data demonstrate that the topical application of CBD regulates over 150 genes in the skin. This likely affects wound healing, pigmentation, aging, acne, and more—all important considerations for companies developing skincare products.”
Recent research suggests that CBD can also influence the epidermal skin barrier, hydration, and wound healing, which positively affect skin conditions like psoriasis.
Patterns of gene expression differ based on the vehicle, extract purity, and concentration, so Genemarkers recommends additional testing of individual skincare products.
Read more about the presentation of our scientific poster on Cosmetics & Toiletries, a website for cosmetic chemists, product formulators, research scientists, and R&D managers who develop and manufacture cosmetic and personal care products.